Cetuximab in non-melanoma skin cancer

Expert Opinion on Biological Therapy

Volumn 12, Issue 7, 2012, Pages 949-956

  Wollina, Uwe ^a  

^a ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

Author keywords

Cetuximab; Epidermal growth factor receptor; Non melanoma skin cancer; Targeted tumor therapy

Indexed keywords

CETUXIMAB; CISPLATIN; CLINDAMYCIN; CLOBETASONE; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERYTHROMYCIN; FLUOROURACIL; ISOTRETINOIN; METHYLPREDNISOLONE; PREDNISONE; TETRACYCLINE;

ACNEIFORM RASH; ANGINA PECTORIS; ARTICLE; AUTOIMMUNE DISEASE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CARDIOTOXICITY; CHEMORADIOTHERAPY; COLORECTAL CANCER; CONTACT ALLERGY; DIARRHEA; DOWN REGULATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; ECTROPION; ECZEMA; GRANULOMA; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEART FAILURE; HEART INFARCTION; HIDRADENITIS; HISTOPATHOLOGY; HUMAN; HYPERKALEMIA; HYPERTRICHOSIS; HYPOCALCEMIA; HYPOCHLOREMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFUSION REACTION; LEUKOPENIA; MEDLINE; METASTASIS; MUCOSA INFLAMMATION; NAIL DECOLORATION; NAIL DISEASE; NAIL PITTING; NAIL PLATE LOSS; NEUTROPENIA; NON MELANOMA SKIN CANCER; ONYCHOLYSIS; PARONYCHIA; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; POSTINFLAMMATORY HYPERPIGMENTATION; PRURITUS; PUSTULE; RADIATION DERMATITIS; RASH; RISK FACTOR; SKIN DISEASE; SKIN FISSURE; SYSTEMATIC REVIEW; TELANGIECTASIA; TRANSIENT ACANTHOLYTIC DERMATOSIS; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME; ULCER; XEROSIS CUTIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN NEOPLASMS;

EID: 84862187887     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.681374     Document Type: Article

References (78)

1. Schmitt J, Seidler A, Diepgen TL, Bauer A. Occupational ultraviolet light exposure increases the risk for the development of cutaneous squamous cell carcinoma: A systematic review and meta-analysis. Br J Dermatol 2011;164:291-307
2. Stang A, Ziegler S, Buchner U, et al. Malignant melanoma and nonmelanoma skin cancers in Northrhine-Westphalia, Germany: A patient- vs. diagnosis-based incidence approach. Int J Dermatol 2007;46:564-70
3. Brewster DH, Bhatti LH, Inglis JH, et al. Recent trends in incidence of nonmelanoma skin cancer in the East of Scotland, 1992-2003. Br J Dermatol 2007;156:1295-300
4. Revenga Arranz F, Paricio Rubio JF, Mar Vasquez Salvado M, del Villar Sordo V. Descriptive epidemiology of basal cell carcinoma and cutaneous squamous cell carcinoma in Soria (north-east Spain) 1998-2000: A hospital-based survey. J Eur Acad Dermatol Venereol 2004;18:137-41
5. Ho T, Byrne PJ. Evaluation and initial management of the patient with facial skin cancer. Facial Plast Surg Clin North Am 2009;17:301-7
6. Jambusaria-Pahlajani A, Miller CJ, Quon H, et al. Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: A systematic review of outcomes. Dermatol Surg 2009;35:574-85
7. Pingnon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Lancet 2000;355:949-55
8. Cranmer LD, Engelhardt C, Morgan SS. Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist 2010;15:1320-8. Excellent review of non-surgical approached to advanced cutaneous SCC.
9. Amini S, Viera MH, Valins W, Berman B. Nonsurgical innovations in the treatment of nonmelanoma skin cancer. J Clin Aesthetic Surg 2010;3:20-34. Excellent review of non-surgical approached to advanced cutaneous SCC.
10. Wollina U, Hansel G, Koch A, Kostler E. Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin. J Cancer Res Clin Oncol 2005;131:300-4
11. Jirakulaporn T, Endrizzi B, Lindgren B, et al. Capecitabine for skin cancer prevention in solid organ-transplanted recipients. Clin Transplant 2011;25(4):541-8
12. Wollina U. Histochemistry of the human hair follicle. EXS 1997;78:31-58
13. Wollina U, Frenkl A, Knoll B, et al. Inhibition of signal transduction in EGF-dependent epithelial cell lines. Int J Mol Med 2003;12:673-7
14. Uribe P, Gonzalez S. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: Molecular bases for EGFR-targeted therapy. Pathol Res Pract 2011;207:337-42
15. Brand TM. The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov Med 2011;12:419-32. Comprehensive review of EGFR signaling and cancer.
16. Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1:1311-18.. Classical study of cetuximab in animal cancer models.
17. Humbert Y. Cetuximab: An IgG1 monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours. Expert Opin Pharmacother 2004;5:1621-33
18. Harding J, Burtness B. Cetuximab: An epidermal growth factor receptor chimeric human-murine monoclonal antibody. Drugs Today (Barc) 2005;41:107-27
19. Cunninham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
20. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78
21. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27
22. Sharafinski ME, Ferris RL, Ferrone S, Grandis JR. Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck 2010;32:1412-21
23. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors - impact on future treatment strategies. Nat Rev Clin Oncol 2010;9:493-507
24. Niyazi M, Maihoefer C, Krause M, et al. Radiotherapy and "new" drugs - new side effects?Radiat Oncol 2011;6:177
25. Robert F, Ezekiel MP, Spencer SA. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:3234-43
26. Bonner JA, Harari PM Giral J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase III randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-8
27. Jensen AD, Bergmann ZP, Garcia-Huttenlocher H, et al. Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck (SCCHN) in the elderly and multimorbid patient: A single-centre experience. Head Neck Oncol 2010;2:34
28. Dequanter D, Shala M, Paulus P, Lothaire P. Cetuximab in the treatment of head and neck cancer: Preliminary results outside clinical trials. Cancer Manag Res 2010;2:165-8
29. Walsh L, Gillham C, Dunne M, et al. Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). Radiother Oncol 2011;98:38-41
30. Comet B, Kramar A, Faivre-Rierret M, et al. Salvage stereotactic reiradiation with or without cetuximab for locally recurrent head-and-neck cancer: A feasibility study. Int J Radiat Oncol Biol Phys 2012; In press
31. Fogarty GB, Conus NM, Chu J, McArthur G. Characterization of the expression and activation of the epidermal growth factor receptor in squamous cell carcinoma of the skin. Br J Dermatol 2007;156:92-8
32. Schlauder SM, Calder KB, Moody P, Morgan MB. HER2 and EGFR expression in cutaneous spindle squamous cell carcinoma. Am J Dermatopathol 2007;29:559-63
33. Maubec E, Duvillard P, Velasco V, et al. Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin. Anticancer Res 2005;25:1205-10
34. Maubec E, Petrow P, Scheer-Senyarich I, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011;29:3419-26.. The first prospective controlled trial of cetuximab in NMSC.
35. Bauman JE, Eaton KD, Martins RG. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol 2007;143:889-92
36. Suen JK, Bressler L, Shord SS, et al. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs 2007;18:827-9
37. Laili A, Pinc A, Pieczkowski F, et al. Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges 2008;6:1066-9
38. Arnold AW, Bruckner-Tuderman I, Zuger C, Itin PH. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. Dermatology 2009;219:80-3
39. Rubio Casadevall J, Grana-Suarez B, Hernandez-Ygue X, et al. Xeroderma pigmentosum: Neck lymph node metastasis of a squamous cell carcinoma of the skin treated with cetuximab. Eur J Dermatol 2009;19:163-5
40. Miller K, Sherman W, Ratner D. Complete clinical response to cetuximab in a patient with metastatic cutaneous squamous cell carcinoma. Dermatol Surg 2010;36:2069-74
41. Kanakamedala MR, Packianathan S, Vijayakumar S. Lack of cetuximab induced skin toxicity in a previously irradiated field: Case report and review of the literature. Radiat Oncol 2010;5:38
42. Kim S, Eleff M, Nicolaou N. Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck. Head Neck 2011;33:286-8
43. Wollina U, Schreiber A, Merla K, Haroske G. Combined cetuximab and volumetric modulated arc-radiotherapy in advanced recurrent squamous cell carcinoma of the scalp. Dermatol Rep 2011;3:e57
44. Giacchero D, Barriere J, Benezery K, et al. Efficacy of cetuximab for unresectable or advanced cutaneous squamous cell carcinoma - a report of eight cases. Clin Oncol (R Coll Radiol) 2011;23:716-18
45. Caron J, Dereure O, Kerob D, et al. Metastatic basal cell carcinoma: Report of two cases treated with cetuximab. Br J Dermatol 2009;161:702-3
46. Gessner K, Wichmann G, Boehm A, et al. Therapeutic options for treatment of merkel cell carcinoma. Eur Arch Otorhinolaryngol 2011;268:443-8
47. Ishiguro M, Watanabe T, Yamaguchi K, et al. A Japanese post-marketing surveillance of cetucimab (Erbitux) in patients with metastatic colorectal cancer. Jpn J Clin Oncol 2012;42(4):287-94. Large trial with post-marketing safety data of cetuximab.
48. Song X, Long SR, Barber B, et al. Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer. Curr Clin Pharmacol 2012;7:56-65
49. Mittmann N, Seung SJ. Rash rates with EGFR inhibitors: Meta-analysis. Curr Oncol 2011;18:e54-63
50. Foley KA, Wang PF, Barber BL, et al. Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab. Ann Oncol 2010;21:1455-61
51. Hoag JB, Azizi A, Doherty TJ, et al. Association of cetuximab with adverse pulmonary events in cancer patients: A comprehensive review. J Exp Clin Cancer Res 2009;28:113
52. De Vos FY, Driessen CM, Jaspers HC, et al. Cetuximab-induced pneumonitis in head and neck cancer patients. Oral Oncol 2012; In press
53. Leard LE, Cho BK, Jones KD, et al. Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. J Heart Lung Transplant 2007;26:1340-4
54. Criado PR, Lima AA. Blepharitis and trichomegaly induced by cetuximab. An Bras Dermatol 2010;85:919-20
55. Ramirez-Soria MP, Espana-Gregori E, Avino-Martinez J, Pastor-Pascual F. Blepharitis related to cetuximab treatment in an advanced colorectal cancer patient. Arch Soc Esp Oftalmol 2008;83:665-8
56. Turan H, Kaya E, Gurlevik Z, et al. Neutrophilic eccrine hidradenitis induced by cetuximab. Cutan Ocul Toxicol 2011; In press
57. Budach W, Bolke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Dermatol 2007;357:514-15
58. Pollack BP, Sapkota B, Cartee TV. Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes. Clin Cancer Res 2011;17:4400-13
59. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16:1425-33.. Detailed review of cetuximab-associated cutaneous toxicities.
60. Ocvirk J, Cencelj S. Management of cutaneous side-effects of cetuximab therapy in patients with matastatic colorectal cancer. J Eur Acad Dermatol Venereol 2010;24:453-9
61. Santiago F, Goncalo M, Resi JP, Figueiredo A. Adverse cutaneous reactions to epidermal growth factor receptor inhibitors: A study of 14 patients. An Bars Dermatol 2011;86:483-90
62. Pinto C, Barone CA, Girolomoni G, et al. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist 2011;16:228-38.. Excellent paper on management of cetuximab-induced cutaneous toxicities.
63. Taguchi K, Fukunaga A, Okuno T, Nishigori C. Successful treatment with adapalene of cetuximab-induced acneiform eruptions. J Dermatol 2011;doi:10.111/j.1346- 8138.2011.01424.x.
64. Eiling E, Brandt M, Schwarz T, Hauschild A. Pimecrolimus: A novel treatment for cetuximab-induced papulopustular eruption. Arch Dermatol 2008;144:1236-8
65. Jatoi A, Rowland K, Sloan JA, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008;113:847-53
66. Gobbo M, Ottavani G, Mustacchi G, et al. Acneiform rash due to epidermal growth factor receptor inhibitors: High-level laser therapy as an innovative approach. Lasers Med Sci 2011; In press
67. Amitay-Laish I, David M, Stemmer SM. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: An early and a late phase of papulopustular eruptions. Oncologist 2010;15:1002-8
68. Orditura M, De Vita F, Galizia G, et al. Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: A single institution retrospective analysis. Oncol Rep 2009;21:1023-8
69. Klinghammer K, Knodler M, Schmittel A, et al. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res 2010;16:304-10
70. Jatoi A, Thrower A, Sloan JA, et al. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash?Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4). Oncologist 2010;15:1016-22
71. Wollina U. Acute paronychia: Comparative treatment with topical antibiotic alone or in combination with corticosteroid. J Eur Acad Dermatol Venereol 2001;15:82-4
72. Caro I, Low JA. The role of the hedgehog signalling pathway in the development of basal cell carcinoma and opportunities for treatment. J Clin Cancer 2010;16:3335-9
73. Galer CE, Corey CL, Wang Z, et al. Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I reduces angiogenesis and tumor growth in cutaneous squamous cell carcinoma. Head Neck 2011;33:189-98
74. Tomkova H, Kohoutek M, Zabojnikova M, et al. Cetuximab-induced cutaneous toxicity. J Eur Acad Dermatol Venereol 2010;24:692-6
75. Garibaldi DC, Adler RA. Cicatrical ectropion associated with treatment of metastatic colorectal cancer with cetuximab. Ophthal Plast Reconstr Surg 2007;23:62-3
76. Tsuboi K, Kawase Y, Okochi O, et al. Cetuximab-associated skin ulceration in patients with metastatic colorectal cancer: A case report. Gan To Kagaku Ryoho 2011;38:1549-52
77. Eames T, Kroth J, Flaig MJ, et al. Perifollicular xanthomas associated with epidermal growth factor receptor inhibitor therapy. Acta Derm Venereol 2009;90:202-3
78. Tscharner GG, Buhler S, Borner M, Hunziker T. Grover's disease induced by cetuximab. Dermatology 2006;213:37-9